Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated With a Reduction in Monthly Migraine Days: A Pooled Analysis of 2 Open-Label Trials
Yu S, Fullerton T, Pixton G, Zou Y, Zhong Q, Zhu H
EHC 2024
- 欧洲头痛大会 2024
| 偏头痛
Consistency of Effect of Rimegepant as An Acute Treatment for Migraine Attacks: Data From A Real-World Survey
Abraham L, Brown J, Hygge-blakeman K, Dai F, Jackson J, Whitton W, Hancock L
EHC 2024
- 欧洲头痛大会 2024
| 偏头痛
Characterisation and Treatment of Patients With Menstrual Migraine in Real-World Clinical Practice
Ailani J, Terwindt G, Galabova B, Cirillo J, Jenkins A, Abraham L, Hygge Blakeman K, Jackson J, Barlow S, Whitton W, Hancock L
EHC 2024
- 欧洲头痛大会 2024
| 偏头痛
Long-Term Safety and Discontinuation for Rimegepant Versus Lasmiditan in The Acute Treatment of Migraine: A Matching-Adjusted Indirect Comparison
Rogula B, De Brún C, Powell L, Jenkins A, Kitano T, Atkinson J, Abraham L
EHC 2024
- 欧洲头痛大会 2024
| 偏头痛
Rimegepant for the Acute Treatment of Migraine: A Phase 3, Multicenter, Open-Label, Long-Term Safety Study in Adults From China
Yu S, Ma L, Zhong Q, Han X
EHC 2024
- 欧洲头痛大会 2024
| 偏头痛
Characterization of Patients Prescribed Rimegepant Compared to all Patients Seeking Migraine Care via Telemedicine
Lewis M, Xiang C, Jenkins A, Abraham L, Hygge Blakeman K, Cirillo J, Crystal S, Livingston M, Song J, Murdoch Ef, Brown J
EHC 2024
- 欧洲头痛大会 2024
| 偏头痛
Acute Medication Overuse in People With Migraine From the 2022 European National Health & Wellness Survey
Coppola G, Gendolla A, Brown J, Lewis M, Jenkins A, Cirillo J, Hygge Blakeman K, Yang J, Abraham L
EHC 2024
- 欧洲头痛大会 2024
| 偏头痛
